Members of Congress Urge FDA to Revise Generic Label Rules

House and Senate lawmakers reacted to the June 24 Supreme Court ruling exonerating generic drugmakers from injury liability by urging the FDA to expedite its review of drug labeling regulations and revise them to allow generic manufacturers to update patient safety information.
Washington Drug Letter